Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 16/20 | 1.00 |
| ▸ | HTR3A | P46098 | 6/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15532751 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL11916930 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL2898244 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL2897455 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL12237717 | 0.87 | CHRNA7 (0.76) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL12237718 | 0.87 | CHRNA7 (0.76) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL2195403 | 0.86 | CHRNA7 (0.74) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL2198137 | 0.86 | CHRNA7 (0.74) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL28539819 | 0.85 | CHRNA7 (0.74) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL1101748 | 0.85 | CHRNA7 (0.76) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2016-05-05 | — | — | US | disclosed |
| US-9067931-B2 | 2-heteroaryl carboxamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20140350008-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-8884017-B2 | 2-heteroarylcarboxylic acid amides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| US-20120258964-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120202842-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2012-08-09 | — | — | US | disclosed |
| US-8076355-B2 | 2-heteroarylcarboxylic acid amides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-13 | — | — | US | disclosed |
| US-8076355-B2 | 2-heteroarylcarboxylic acid amides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-7977485-B2 | 2-heteroaryl carboxamides | BAYER SCHERING PHARMA AKTIENGESELLSHAFT (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| EP-1461335-B1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1515967-B1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
| EP-1515967-A1 | 2-HETEROARYL CARBOXAMIDES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003104227-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | HCAR2, HCAR1, GRIN2A | CHRNA7 354/4885HTR3A 637/4885HTR3E 785/4885 |
| US-20140350008-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | CHRNA7 70/4885HTR3A 205/4885HTR3E 278/4885 |
| US-20120258964-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | CHRNA7 70/4885HTR3A 205/4885HTR3E 278/4885 |
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | CHRNA7 70/4885HTR3A 205/4885HTR3E 278/4885 |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | GRIN2A, CNR2, GRIN2C | CHRNA7 70/4885HTR3A 205/4885HTR3E 278/4885 |
| US-20120202842-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | HCAR2, HCAR1, GRIN2A | CHRNA7 354/4885HTR3A 637/4885HTR3E 785/4885 |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | CHRNA7 70/4885HTR3A 205/4885HTR3E 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.